Event Information
Event Topic:
Embracing the Unpredictable: Lessons from the Past and Present of a Life of Biotech Company
Event Description:
In this presentation, Dinesh V. Patel, PhD, President and CEO of Protagonist Therapeutics, will offer reflections on his company’s experiences in navigating and overcoming unexpected obstacles, including a CRO error that nearly collapsed the company in 2018. Dr. Patel will also present insights into Protagonist’s recent experience with an FDA Clinical Hold and its record removal in less than 3 weeks, providing lessons in crisis management relevant to biotech companies of every size and stage. It has been an extraordinary journey with a $9M series A financing in 2009 to its current billion dollar plus market cap (Nasdaq Symbol: PTGX), with numerous lessons in resilience, humility, and conviction.
Date/Time:
Date(s) - 11/09/21
6:30 pm - 8:30 pm
Event Location:
Zoom talk: https://us02web.zoom.us/j/88274227563:
Speaker Information
Event Speaker:
Dinesh Patel
Event Speaker Title:
President & CEO
Event Speaker Company:
Protagonist Therapeutics
Event Speaker Bio:
Dr. Patel has served as a member of the board of directors and as the President and Chief Executive Officer of Protagonist since December 2008. He has 33 years of executive, entrepreneurial, and scientific experience that span the pharmaceutical, biotechnology and biopharmaceutical industries. Prior to joining Protagonist Therapeutics, Dr. Patel served from 2006 to 2008 as the President and Chief Executive Officer of Arête Therapeutics, a privately held company focused on novel drugs for metabolic syndrome. Previously, he was the Chief Executive Officer and Cofounder of Miikana Therapeutics, an oncology-based company, from 2003 until acquired by Entremed (later renamed CASI Pharmaceuticals) in 2005. Prior to Miikana, Dr. Patel held positions of increasing responsibility at Versicor (later renamed Vicuron) from 1996 to 2003, most recently as Senior Vice President of Drug Discovery and Licensing. Vicuron research and development efforts led to two marketed drugs, anidulafungin (Eraxis®), and Dalbavancin (Dalvance®), and the Company was acquired by Pfizer in 2005 in a $1.9 billion cash transaction. From 1993 to 1996, Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax. Dr. Patel was a medicinal chemist at Bristol-Myers Squibb from 1985 to 1993. Dr. Patel received his Ph.D. in Chemistry from Rutgers University, New Jersey and his B.S. in Industrial Chemistry from S. P. University, Vallabh Vidyanagar, India
Event Details
Cost:
$0
Add To Calendar
